EVINACUMAB (Evkeeza) Nursing Considerations

What is the generic name?

EVINACUMAB

What is the Trade Name for EVINACUMAB?

Evkeeza

What are the Indications for EVINACUMAB?

• 1 INDICATIONS AND USAGE EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH). EVKEEZA is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH). ( 1 ) Limitations of Use: The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined. ( 1 ) Limitations of Use: The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

References: https://open.fda.gov/